BTIG Upgrades Globus Medical to Buy, Announces $60 Price Target
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Ryan Zimmerman upgrades Globus Medical (NYSE:GMED) from Neutral to Buy and sets a $60 price target.

March 18, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Globus Medical upgraded from Neutral to Buy by BTIG analyst Ryan Zimmerman, with a new price target of $60.
Analyst upgrades typically lead to positive short-term price movements as they reflect a positive change in the analyst's view of the company's future performance. The upgrade from Neutral to Buy suggests a strong confidence in the company's potential for growth or improvement. Additionally, setting a price target of $60, which is presumably higher than the current trading price, indicates an expectation of upward movement in the stock's price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100